Drugs & Medical Devices
DePuy Hip Implants Device Failures
|
DePuy Orthopaedics
Company Issued Warning Letters in Conjunction with Other DePuy Hip Implant Problems
Less than one week before DePuy Orthopaedics issued a worldwide recall of their DePuy ASR or DePuy ASR XL hip system devices, the U.S. Food and Drug Administration (FDA) issued the following letter to the company. The FDA issued the warning letter to DePuy to address alleged marketing compliance issues with two devices unrelated to the ASR hip recall.
As a public service for DePuy hip replacement patients, our defective medical device injury lawyers are providing the content in this letter.
DePuy hip implant patients who received the ASR or ASR XL devices subject to the DePuy hip recall can obtain vital information about their legal options by completing the form on this page.
WARNING LETTER
August 19, 2010
The Food and Drug Administration (FDA) has learned that your firm is marketing the TruMatchTM Personalized Solutions System and the Corail® Hip System in the United States (U.S.) without the required marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).
The Office of Compliance (OC) in the Center for Devices and Radiological Health (CDRH) reviewed your website for the TruMatchTM Personalized Solutions System and the Corail® Hip System. The products are devices within the meaning of section 201(h) of the Act 21 U.S.C. § 321(h), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body. The Act requires that manufacturers of devices that are not exempt obtain marketing approval or clearance for their products from the FDA before they may offer them for sale. This helps protect the public health by ensuring that new devices are shown to be both safe and effective or substantially equivalent to other devices already legally marketed in this country for which approval is not required.
TruMatch™
A review of our records reveals that you have not obtained marketing approval or clearance before you began offering the TruMatch™ Personalized Solutions System for sale, which is a violation of the law. Specifically, the TruMatch™ Personalized Solutions System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for investigational device exemptions (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution. as required by section 510(k) of the Act, 21 U.S.C. 360(k).
For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency. 21 C.F.R. 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.
Corail® Hip System
A review of our records indicates that we cleared a premarket notification (510(k)) for the Corail® Hip System, K042992, with an intended use for total hip arthroplasty "to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components." In addition, total hip replacement is indicated in the following conditions:
1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia.
2. Avascular necrosis of the femoral head.
3. Acute traumatic fracture of the femoral head or neck.
4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement.
5. Certain cases of ankylosis.
The non-porous Corail AMT Hip Stem is indicated for cementless use only.
However, a brochure on your website states the following claims about the Corail® Hip System:
Promotion of this device for osseointegration (a.k.a. osteointegration), whether explicitly or implicitly (for example, through fixation claims that imply osseointegration). represent a major change or modification in the intended use of your device that require a new premarket notification. 21 CFR 807.81(a)(3)(ii). Because of these claims, the Corail® Hip System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section, 502(o) of the Act, 21.U.S.C. 352(o), because you did not submit to FDA a notification respecting the changes to the intended use of the device, as required by section 510(k) of the Act, 21 U.S.C. 360(k), and 21 CFR 807.81(a)(3)(ii).
FDA requests that DePuy Orthopaedics, Inc. immediately cease marketing the Corail® Hip System for unapproved uses such as those described above. You should take prompt action to correct the violations listed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the Food and Drug Administration without further notice. These actions include, but are not limited to seizure, injunction, and/or civil money penalties.
Please notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations for the TruMatch™ Personalized Solutions System and the Corail® Hip System, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrective action you have taken. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Please include in your response a list all promotional materials for the Corail® Hip System containing claims for unapproved uses such as those described above, and explain your plan for discontinuing such claims.
Get Help from Weitz & Luxenberg
If you have experienced complications from a DePuy ASR hip implant, our defective medical device lawyers may be able to help you obtain compensation for your injuries, pain and suffering and other legal relief.
Please complete the form on this page to have your possible DePuy hip lawsuit reviewed by our law firm.
A Weitz & Luxenberg representative will contact you as soon as possible.
see also:
Hip Replacement Lawsuit
Hip Replacement Lawsuit - Call Weitz & Luxenberg for a free case reviewFaulty hip replacement? Discover the possibility of a lawsuit.
Hip Implant Lawyer
Hip Implant Failure Lawyer, Lawsuit and Class ActionDo you know about failed DePuy hip implants? Hear from our lawyers.
ASR Problems
DePuy Hip Implant Problems | News From Weitz & Luxenberg LawyersDid you experienced problems or need additional replacement surgery after a DePuy hip implant? Discuss your situation and get important legal information
